While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

A small player like Viking may also win by attracting a partner or even a company that will offer to acquire the biotech.

Novo Nordisk A/S’s appetite-blocking shot semaglutide, sold under the brand names Ozempic and Wegovy ... the US for diabetes ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

So how does tirzepatide work and differ from Ozempic? And with a price tag of $315–$645 per month for the starting dose, why is it ... acts on one (GLP-1). This dual action is thought to be ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

In humans, nasal foralumab modulates immune responses by inducing regulatory-type T cells. Semaglutide is an effective ...

As weight-loss injections emerge as key players in the government’s anti-obesity strategy, Emma Loffhagen goes inside the ...

Lexaria Bioscience Corp., a global innovator in drug delivery platforms announced that dosing has begun, for human pilot study #3, investigating a DehydraTECH-processed version of the dual action ...